Company

Myopharm Limited

Biotechnology Au 5 employees

Employees: 5
Contacts: 3
Emails: 3

myostin.com LinkedIn

Myopharm Limited Overview

Headquarters: Au
Website: myostin.com
Industry: Biotechnology
Employees: 5

Keywords

Biotechnology Therapeutics Orphan / Rare Diseases metabolic diseases diabetes metabolic syndromes T2D R&D type 2 Diabetes Pre-Diabetes Insulin Resistance IND Approved

About Myopharm Limited

Myopharm is an IND stage biotechnology company focused on developing first in class, novel therapeutics for the treatment and prevention of Type 2 diabetes. Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric dual combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics. Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza™ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza™ to market by 2027. https://www.myopharm.com

Myopharm Limited Contact Details

People in AeroLeads: 3
With contact data: 3
Email contacts: 3; 100.0% coverage

Myopharm Limited Org Chart

Sample employees and titles

Name	Title	Location	Contact
George Tachas	Chief Scientific Officer, Myopharm Ltd	Melbourne, Victoria, Australia	Email
Milton Grannatt		East Hanover, New Jersey, United States	Email
Tamara Miller	Head of Clinical Development	Greater Sydney Area, Australia	Email